Besides targeting CD40, intratumoral injection of fms-related tyrosine kinase 3 ligand or granulocyte–macrophage colony-stimulating factor might also be promising options, because they recruit and activate DCs at the tumor site44–46. This evidence concerns the gene CD40 and neoplasm.